Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study.

Added 604 days ago (23.09.2020)
Authors: Lai S, Mangiulli M, Perrotta AM, Gigante A, Napoleoni L, Cipolloni E, Mitterhofer AP, Gasperini ML, Muscaritoli M, Cianci R, Giovannetti A, Falco F, Mastroluca D, Mazzaferro S
PubMed id: 32957887
Read article